RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $117 to $112.
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $117 to $112.